Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Seungmin Bang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5209-8351; OpenAlex author ID A5050431257, A5064040434. Sources: OpenAlex.

Their work

Papers
62 (first author 0, last author 23)
Trials
0
Grants
0
Labs led
1
Collaborators
107
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 4 papers · 2014: 4 papers · 2015: 1 paper · 2016: 6 papers · 2017: 5 papers · 2018: 3 papers · 2019: 4 papers · 2020: 6 papers · 2021: 6 papers · 2022: 8 papers · 2023: 5 papers · 2024: 5 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 62

  1. Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3348/kjr.2025.1394↗
  2. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Co-author DOI 10.1016/j.pan.2025.02.007↗
  3. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  4. Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer. Last author DOI 10.1186/s12943-025-02374-y↗
  5. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/cam4.70363↗
  6. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. Last author DOI 10.1038/s41598-024-52909-4↗
  7. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Last author DOI 10.1177/17588359241279688↗
  8. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  9. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy. Co-author DOI 10.4143/crt.2023.586↗
  10. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Co-author DOI 10.1007/s00330-023-09584-2↗
  11. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.02.049↗
  12. Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2045↗
  13. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Last author DOI 10.1210/clinem/dgac728↗
  14. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
  15. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34144↗
  16. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1025↗
  17. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. Co-author DOI 10.1038/s41598-022-22126-y↗
  18. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Co-author DOI 10.1148/radiol.212236↗
  19. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  20. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Last author DOI 10.3390/cancers14051244↗
  21. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Last author DOI 10.3390/cancers14194672↗
  22. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Last author DOI 10.5009/gnl20301↗
  23. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Co-author DOI 10.1007/s00261-020-02661-w↗
  24. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Last author DOI 10.1016/j.ebiom.2021.103218↗
  25. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jgh.15265↗
  26. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  27. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  28. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. Co-author DOI 10.2196/21088↗
  29. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Last author DOI 10.1007/s00280-020-04051-x↗
  30. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Last author DOI 10.1016/j.pan.2020.05.017↗
  31. Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001687↗
  32. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Last author DOI 10.1111/jgh.14837↗
  33. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Last author DOI 10.4251/wjgo.v12.i2.182↗
  34. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Last author DOI 10.5009/gnl18419↗
  35. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Last author DOI 10.1002/cam4.2210↗
  36. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Co-author DOI 10.1080/01635581.2019.1597906↗
  37. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001319↗
  38. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  39. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Co-author DOI 10.1038/s41598-018-21823-x↗
  40. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i11.421↗
  41. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. Last author DOI 10.4251/wjgo.v10.i12.505↗
  42. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Last author DOI 10.1053/j.seminoncol.2018.01.001↗
  43. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. Co-author DOI 10.1080/01635581.2016.1250921↗
  44. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  45. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  46. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Co-author DOI 10.5009/gnl16526↗
  47. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Last author DOI 10.1016/j.dld.2015.12.006↗
  48. Visceral Obesity is Associated with Poor Prognosis in Pancreatic Adenocarcinoma. Co-author DOI 10.1080/01635581.2016.1134600↗
  49. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Last author DOI 10.1097/md.0000000000003607↗
  50. Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0157196↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hee Seung Lee · 40 shared papers, 2016–2025 · strength 5.10
  2. Moon Jae Chung · 48 shared papers, 2013–2026 · strength 5.05
  3. Jeong Youp Park · 47 shared papers, 2011–2025 · strength 4.75
  4. Seung Woo Park · 45 shared papers, 2011–2025 · strength 4.43
  5. Si Young Song · 42 shared papers, 2011–2024 · strength 3.73
  6. Jung Hyun Jo · 25 shared papers, 2014–2025 · strength 3.39
  7. Mi‐Suk Park · 12 shared papers, 2017–2025 · strength 1.85
  8. Ho Kyoung Hwang · 12 shared papers, 2013–2026 · strength 1.51
  9. Seung‐seob Kim · 8 shared papers, 2020–2025 · strength 1.35
  10. Huapyong Kang · 12 shared papers, 2014–2024 · strength 1.24
  11. Chang Moo Kang · 11 shared papers, 2013–2024 · strength 1.20
  12. Jiyoung Keum · 7 shared papers, 2020–2025 · strength 1.07
  13. Jae Bock Chung · 12 shared papers, 2013–2025 · strength 0.89
  14. Woo Jung Lee · 8 shared papers, 2013–2022 · strength 0.58
  15. Kyung In Shin · 3 shared papers, 2024–2025 · strength 0.56
  16. Jae Hee Cho · 3 shared papers, 2022–2025 · strength 0.53
  17. Sung Ill Jang · 3 shared papers, 2022–2025 · strength 0.53
  18. Sang Hoon Lee · 5 shared papers, 2016–2024 · strength 0.46
  19. Jinsil Seong · 5 shared papers, 2013–2024 · strength 0.39
  20. Jin Su Kim · 2 shared papers, 2024–2025 · strength 0.38
  21. Dawoon Jung · 3 shared papers, 2018–2023 · strength 0.38
  22. Jee Hoon Kim · 2 shared papers, 2024–2025 · strength 0.38
  23. In Rae Cho · 5 shared papers, 2013–2021 · strength 0.37
  24. Man Deuk Kim · 2 shared papers, 2021–2026 · strength 0.37
  25. Joon Ho Kwon · 2 shared papers, 2021–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.